Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.

Abstract

Extended adjuvant endocrine therapy (10 vs. 5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer; however, the absolute benefit is modest, and toxicity and tolerability challenges remain. Predictive and prognostic information from genomic analysis may help inform this clinical decision. The purpose of this study was to assess the impact of the Breast Cancer Index (BCI) on physician recommendations for extended endocrine therapy and on patient anxiety and decision conflict. Patients with stage I-III, ER-positive breast cancer who completed at least 3.5 years of adjuvant endocrine therapy were offered participation. Genomic classification with BCI was performed on archived tumor tissues and the results were reported to the treating physician who discussed results with the patient. Patients and physicians completed pre- and post-test questionnaires regarding preferences for extended endocrine therapy. Patients also completed the validated traditional Decisional Conflict Scale (DCS) and State Trait Anxiety Inventory forms (STAI-Y1) pre- and post-test. 96 patients were enrolled at the Yale Cancer Center [median age 60.5 years (range 45-87), 79% postmenopausal, 60% stage I). BCI predicted a low risk of late recurrence in 59% of patients versus intermediate/high in 24 and 17%, respectively. Physician recommendations for extended endocrine therapy changed for 26% of patients after considering BCI results, with a net decrease in recommendations for extended endocrine therapy from 74 to 54%. After testing, fewer patients wanted to continue extended therapy and decision conflict and anxiety also decreased. Mean STAI and DCS scores were 31.3 versus 29.1 (p = 0.031) and 20.9 versus 10.8 (p < 0.001) pre- and post-test, respectively. Incorporation of BCI into risk/benefit discussions regarding extended endocrine therapy resulted in changes in treatment recommendations and improved patient satisfaction.

• Authors: Tara Sanft, Bilge Aktas, Brock Schroeder, Veerle Bossuyt, Michael DiGiovanna, Maysa Abu-Khalaf, Gina Chung, Andrea Silber, Erin Hofstatter, Sarah Mougalian, Lianne Epstein, Christos Hatzis, Cathy Schnabel, Lajos Pusztai
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 154 Issue 3 Pg. 533-41 (Dec 2015) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 26578401 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Receptors, Estrogen
• Tamoxifen

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Agents, Hormonal (therapeutic use)
• Anxiety (psychology)
• Breast Neoplasms (drug therapy, pathology, psychology)
• Chemotherapy, Adjuvant
• Decision Making
• Female
• Gene Expression Regulation, Neoplastic
• Genetic Testing
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Prognosis
• Prospective Studies
• Receptors, Estrogen (metabolism)
• Surveys and Questionnaires
• Tamoxifen (therapeutic use)